Mytesi works differently from most other antidiarrheal medications1,2

Mytesi is an antisecretory that regulates the CFTR and CaCC ion channels, resulting in normalization of fluid and electrolyte balance in the GI tract1,3,*

Mytesi works to restore balance

Normal

Chloride ion (Cl-) channels in the GI tract maintain a balance of water and salts—including chloride ions—that allows normal stool formation

Diarrhea

HIV or its treatment can cause damage to the GI tract, creating inflammation and a leaky gut
This can further disrupt the balance of chloride ions and water flow into the gut lumen, leading to secretory diarrhea

HIV or its treatment can cause damage to the GI tract, creating inflammation and a leaky gut

This can further disrupt the balance of chloride ions and water flow into the gut lumen, leading to secretory diarrhea

Mytesi

Mytesi works by regulating two chloride ion channels (CFTR and CaCC) in the GI tract, which normalizes the salt-water balance, leading to a decrease in chloride and water flow1,3,4

Because it is a nonopioid, Mytesi does not affect gastrointestinal motility and has a low risk of constipation1,2,5

Mytesi helps patients avoid the
diarrhea-constipation cycle

In a clinical study, less than 2% of people on Mytesi reported experiencing constipation.2

Mytesi may reduce
noninfectious diarrhea
in PLWH on ART.

Mytesi is well
tolerated.

*CaCC=calcium-activated chloride channel; CFTR=cystic fibrosis transmembrane conductance regulator.

References:
1. Mytesi [package insert]. San Francisco, CA: Napo Pharmaceuticals. 2018. 2. MacArthur R, Harkins TN, Brown SJ, et al. Efficacy and safety of Crofelemer for non-infectious diarrhea in HIV-seropositive individuals (ADVENT Trial): a randomized, double-blind, placebo-controlled, two-stage study. HIV Clin Trials. 2013;14(6):261-273. 3. Tradtrantip L, Namkung W, Verkman AS. Crofelemer, an antisecretory antidiarrheal proanthocyanidin oligomer extracted from Croton lechleri, targets two distinct intestinal chloride channels. Mol Pharmacol. 2010;77(1):69-78. 4. Holodniy M, Koch J, Mistal M, et al. A double blind, randomized, placebo-controlled phase II study to assess the safety and efficacy of orally administered SP-303 for the symptomatic treatment of diarrhea in patients with AIDS. Am J Gastroenterol. 1999;94(11):3267-3273. 5. MacArthur RD, Clay P, Blick G, Waltzman R, Bell M. Long-term Crofelemer provides clinically relevant reductions in HIV-related diarrhea. 9th IAS Conference on HIV Science (IAS 2017), July 23-26, 2017, Paris, France. Abstract WEPEB0537.